

John D. Lewis, Ph.D.
CEO, Entos Pharmaceuticals

John Lewis holds the Frank and Carla Sojonky Chair in Prostate Cancer Research funded by the Alberta Cancer Foundation at the University of Alberta and is a Professor of Oncology and chair of the Alberta Prostate Cancer Research Initiative. Dr. John Lewis's research interests lie in the areas of nanotechnology and imaging as they relate to infectious disease as well as chronic diseases such as aging



and cancer. The Lewis laboratory uses advanced live imaging techniques to study the spread of cancer, or metastasis, in real time.

Dr. John Lewis is CEO of Entos Pharmaceuticals, an Edmonton-based biotechnology company developing genetic medicines using the Fusogenix drug delivery system. Entos is developing DNA-based vaccine and therapeutic countermeasures for COVID-19 using the Fusogenix platform technology.